Drug- and device-makers wanting the FDA to close out concerns raised in warning letters could have a long wait. So far this year, the agency has issued 14 close-out letters to drug companies for manufacturing problems, promotion violations, and failure to pay facility fees or list products correctly. It's issued 81 closeout letters to device-makers.